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ABSTRACT
Objectives: To investigate the extent of underpresen-
tation of shortness of breath to general practitioners
(GPs) in a random sample of the general population
without a confirmed diagnosis of obstructive airways
disease (OAD).  A second objective was to assess the
influence of a person’s perception of symptoms and
psychological factors as possible causes for under-
presentation.
Design: A random sample of the general population
(n = 1155) was screened for respiratory symptoms.  Of
those who experienced shortness of breath at some
stage during the preceding year, the ability to perceive
dyspnoea was assessed in 134 patients, by means of a
Borg score and a visual analogue scale (VAS) during
each step of a histamine provocation test.  A
psychological profile was assessed in 130 subjects
using five validated questionnaires.
Patients: Two random sample groups (n = 134 and
n = 130) of adults reporting dyspnoea without a
diagnosis of OAD.
Results: Of the initial sample, 285 (25%) had
experienced shortness of breath in the year preceding
the screening: only 93/285 (33%) had ever consulted
their GP for this.  Multivariate analysis showed that
neither a person’s perception of dyspnoea nor
psychological factors could explain underpresentation.
Conclusions: Underpresentation of symptoms is a
major factor contributing to underdiagnosis of OAD,
but this is not related to the patient’s perception of
symptoms nor to their psychological profile.
INTRODUCTION
As with many chronic diseases, a significant
proportion of the general population has obstructive
airways disease (OAD) which is undiagnosed by the
GP.  Comparison of the number of diagnosed cases
from morbidity registration systems with the results of
population surveys indicates that the discrepancy may
be as much as ten-fold. 1–4 The GP has generally been
blamed for this underdiagnosis; 5 however, it is likely
that underpresentation of respiratory symptoms by the
patient may also contribute.  The early symptoms of
OAD are often non-specific and may be ignored, and
the condition may worsen so gradually that patients
adapt to it.
In the Detection, Intervention and Monitoring of
COPD and Asthma (DIMCA) programme, patients
without a confirmed diagnosis of OAD, but with
early signs of OAD, were detected by means of a
two-stage programme consisting of screening
followed by monitoring for up to two years.  The
details of this study have been published elsewhere; 6,7
the results confirm that there is a significant level of
underpresentation.  A large proportion (74%) of
subjects with respiratory problems during the year
preceding the screening never consulted a GP for
this, regardless of the severity.  Of the subjects with
persistently reduced lung function or increased levels
of bronchial hyperresponsiveness and reversibility,
69% did not seek medical help. 7 Poor perception of
symptoms may be a possible explanation of under-
presentation. 8 –10
In our opinion, shortness of breath is the core 
alarm symptom of asthma.  Other symptoms, such 
as cough and phlegm production, are less specific.
The aim of this study was to determine the
prevalence of shortness of breath in the general
population and the extent to which this was 
reported to a GP.  The second aim was to assess 
the extent to which perception of symptoms and
psychological factors explain the underpresentation
of shortness of breath.
METHODS
Design
This study is part of the DIMCA programme, which
aimed to assess the efficacy and cost-effectiveness
of active detection and early treatment of OAD. 6
The programme consisted of detection and
treatment phases.  A random sample of undiagnosed
adult subjects from the general population
(n = 1155), aged between 25 and 70 years, were
invited for screening, consisting of a standardised
respiratory symptoms questionnaire and lung
function assessment.  Subjects with symptoms or
objective signs of OAD or both, were invited to
participate in the second stage of the detection
phase: the monitoring.  In this phase, lung function
and symptoms were measured every three months
for up to two years, during which patients were
selected for the treatment phase.
As part of the screening, subjects were asked whether
they had experienced shortness of breath during the
preceding 12 months and, if so, whether they had
consulted their GP or chest physician for this.  Two
random samples of those reporting shortness of breath
were studied further: one (n = 134) to assess an
individual’s ability to perceive shortness of breath; the
other (n = 130) to assess the role of psychological
factors in relation to medical consultation.
Patient characteristics
The characteristics of patients who experienced
shortness of breath during the year preceding the
screening were compared with those who did not.
Within the group reporting shortness of breath, the
characteristics of those who did and did not consult
their GP were compared.  The VC, FVC, FEV1 and
reversibility were measured using a portable
Microspiro HI-298 (Chest Corporation, Tokyo,
Japan). 11 After instruction, subjects were asked to
perform three unforced and three forced expiratory
manoeuvres from maximum inspiration.  The FEV1
corresponding to the manoeuvre with the highest sum
of the FEV1 and FVC was recorded as the FEV1 at
that moment.  Predicted values were calculated using
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Editorial
Primary care has developed into a majorclinical discipline.  It is an effective andeconomical way of delivering healthcare.
Primary care physicians treat both a wide array of
disease and channel more difficult or unusual
problems into the hospital setting.  All medical
schools in the UK now have departments of general
practice or primary care.
Since its inception the General Practitioners 
In Asthma Group (GPIAG) has aimed to
revolutionise respiratory care in the UK.  A major
step in achieving this aim has been realised by
securing funding from a consortium of
pharmaceutical companies to support a Chair in
Primary Care Respiratory Medicine for a period of
five years.  We are delighted to announce that our
interview panel (Dermot Ryan and David Price, for
the GPIAG, and Robert McKinley and Douglas
Flemming, independent interviewers) awarded 
this post to the Department of General Practice 
and Primary Care at Aberdeen University.  The
professorship will be advertised and an appointment
made later this year.
The professorial post will be a resource to 
develop pertinent, evidence-based solutions, 
to initiate epidemiological and clinical studies; 
to further develop the research network; and to
explore and develop the interface between 
primary and secondary care.  The post will 
support the application of evidence-based medicine
by those working in primary care.  By establishing
this new post, the GPIAG is providing an
opportunity for primary care-led research and
innovation.
Respiratory diseases are major reasons for
consultation in primary care. 1 The primary care
team manages most patients with these problems
exclusively.  Guidelines for the management of
asthma, 2 , 3 COPD 4 and rhinitis 5 have been
produced, but only a few 3 , 4 have had input from
primary care.  Secondary care solutions are not
always appropriate for primary care problems, one
of the reasons for this new post.
The GPIAG Research Unit in Dundee continues to
be responsible for important respiratory research 6 –14
(full bibliography on web page) and runs the group
web page (http://www.gpiag-asthma.org/asthma/
GPIAG/welcome.htm).  Members actively
participate in national and international respiratory
conferences and many have contributed significantly
to the medical literature in the last 20 years. 1 5 The
group has an extensive research network of more
than 250 practices.  Our journal, Asthma in General
Practice, publishes work relevant to primary care
respiratory disease, including abstracts of work
presented at our Annual Scientific Meeting. n
Dr Dermot Ryan
Chairman, GPIAG
Dr David Price
Joint Research Director, GPIAG
Dr Mark Levy
Editor, Asthma in General Practice
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correction for age, gender and height (FEV1
expressed as percentage of the predicted value).
Subjects with shortness of breath had a smaller vital
capacity and a higher level of reversibility after
inhalation of salbutamol.  They had significantly
more pack-years and were more often currently
smokers (Table 1).  Although they experienced
shortness of breath at least once, only 93/285
(32.6%) had ever consulted a GP for this.  Those
who consulted their GP had a higher level of
reversibility and were four years younger, on
average, than those who did not, but there were no
significant differences in FEV1 expressed as a
percentage of the predicted value or vital capacity
nor in smoking status or gender (Table 2).
Poor perception as possible cause of 
underpresentation
In the first sample (n = 134), perception of shortness
of breath was assessed during a histamine
provocation test.  The change in FEV1 induced by
the test was normally distributed with an average of 
-18% (SD 10%).  Most subjects (72%) had a
decrease in FEV1 greater than 10%.  In this
subgroup, 51 (38.1%) had consulted a GP for
respiratory symptoms, a percentage similar to that in
the whole group.  The results from the logistic
regression model showed that a person’s perception
was unlikely to be a significant factor in his decision
to seek medical help.  Perception, defined as the
difference in Borg scores, was not statistically
significantly different (p = 0.51) between those who
consulted a GP and those who did not (Table 3).  As
expected, a person’s perception of symptoms
correlated well with the decrease in FEV1 induced
(the greater the induced dyspnoea, the larger the
perceived difference in dyspnoea).  However, none
of the covariates reached the level of statistical
significance.  The result was similar using the VAS
scores: neither perception of symptoms nor any of
the covariates in the model played a significant role
in medical consultation.  Table 4 presents the results
from the dichotomised analysis: 23 subjects
indicated that they did not perceive shortness of
breath in spite of a decrease in FEV1, induced by
histamine, while the remaining 111 subjects did
perceive the induced dyspnoea, to some extent.
Only 22% of the non-perceivers consulted their GP
compared with 41% of those who did perceive
symptoms.  This almost two-fold difference
approached statistical significance (p = 0.08); the
associated odds ratio was 2.55.
Psychological factors as possible causes of 
underpresentation
A second sample was studied to determine whether
psychological factors were associated with seeking
medical help.  Despite randomisation, a smaller
proportion (20.8%) of this group had consulted their
GP than in the whole group.  None of the
psychological instruments showed significant
differences between those who did and did not
consult a GP for shortness of breath.  Univariate
testing of the differences produced similar results,
indicating that correction for partial correlations did
not influence the outcome.  All differences between
the two groups were very small (the effect sizes
ranged from 0.09 to 0.30).
DISCUSSION
Increasing attention has been paid in recent years to
preventing underdiagnosis of asthma and COPD.
The development of guidelines for diagnosis and
therapy of asthma are examples of efforts in this
Asthma in General Practice 5
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the equations by Quanjer et al. 12 The degree of
reversibility was measured as the change in FEV1
relative to the predicted value after salbutamol
administration.  Current smoking, smoking history
and the number of pack-years were assessed during
the screening.
Perception and medical consultation
Perception of shortness of breath was assessed
during a histamine provocation test. 13 Patients were
instructed to record their experienced level of
shortness of breath 30 seconds after each dose of
histamine and immediately before the FEV1
measurement.  The extent of shortness of breath was
rated on a vertically oriented modified Borg scale,
with a 12-point ordinal scale ranging from 0 (no
breathlessness at all) to 0.5 (very, very slight
breathlessness) to 10 (maximum breathlessness), 13,14
and on an anchorless 100-mm visual analogue scale
(VAS). 15
Psychological factors and medical consultation
The following five validated questionnaires were
completed:
1. The Utrecht Coping List (UCL), 17 of which the
first four scales (Active tackling, Palliative
responses, Avoidance, and Seeking social
support) were used
2. The State-Trait Anxiety Inventory 18
3. Multidimensional Health Locus of Control
Scale, which assesses perceived causes of
health and illness 19
4. The Respiratory Illness Opinion Survey, which
assesses attitudes of patients with respiratory
disorders towards their illness. 20 Two
subscales Optimism and Stigma, were used
5. The Dutch Personality Inventory, of which
only the subscale Inadequacy (neuroticism)
was measured by means of a questionnaire
completed by the patients themselves. 21
Analysis
Differences between patient characteristics were tested
with independent Student’s t tests.  The proportions of
men to women and smokers to non-smokers were
tested by c 2 tests.  The association between a
perception of symptoms and medical consultation was
assessed by a logistic regression analysis, with
consultation with a doctor (0 = no,1 = yes) as the
dependent variable.  Perception of symptoms was
defined as the difference in Borg (VAS) score [the last
Borg (VAS) score minus the baseline Borg (VAS)
score].  A large difference would indicate good
perception; no difference, despite a decrease in FEV1,
would indicate poor perception.  The difference in
Borg (VAS) entered the equation as an explanatory or
independent variable.  The change in FEV1 during
histamine provocation, baseline Borg (VAS), baseline
FEV1 and age were entered as covariates in the
analysis.  All possible interaction effects
(multiplicative) were also entered in the model.  In the
case of a non-interaction model, the results from the
reduced model (for example, without the interaction
terms) were presented.  A forward procedure to enter
the variables in the equation was used: inclusion of
variables was based on a likelihood function (SPSS
6.0 for Windows: Logistic Regression; Forward
Likelihood).  In a second analysis, perception was
dichotomised. Subjects who had a difference in Borg
(VAS) score equal to zero, in spite of a decrease in
FEV1, were labelled ‘non-perceivers’ whereas the
remainder of the sample was labelled ‘perceiver’.  The
association between psychological factors and medical
consultation was assessed in a similar way by logistic
regression analysis.  In this analysis, whether or not a
doctor was consulted was entered into the analysis as
the dependent variable, and the scale scores from the
psychological tests were entered as independent
variables, including all one-by-one interaction terms
(multiplicative).
RESULTS
Underpresentation of shortness of breath in the
general population
Of all subjects screened 285/1155 (24.7%) had
experienced shortness of breath during the year
preceding the screening.  These subjects had a
significantly lower FEV1, indicating airways
obstruction.  This difference remained after
Asthma in General Practice4
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Variables ß Standard error p
Dependent variable
Consultation (0 = no; 1 = yes)
Main effect
Difference in Borg score 0.09 0.13 0.51
Covariates
Percentage change in FEV1 - 3.27 1.96 0.09
Baseline Borg score 0.14 0.17 0.40
Baseline FEV1 < 0.01 < 0.01 0.43
Age < - 0.01 0.02 0.60
Dependent variable
Consultation (0=no; 1=yes)
Main effect
Difference in VAS score 0.01 0.01 0.34
Covariates
Percentage change in FEV1 - 3.26 1.92 0.09
Baseline VAS score 0.01 0.01 0.38
Baseline FEV1 < 0.01 < 0.01 0.31
Age - 0.01 0.02 0.75
Table 3: Association between perception of shortness of breath and medical
consultation due to shortness of breath: Results of logistic regression
analysis
Factors ß Standard error p
Dependent variable:
Consultation (0=no; 1=yes)
Main effect:
Utrecht Coping List
Active tackling - 0.08 0.09 0.37
Palliative responses - 0.10 0.13 0.45
Avoidance 0.01 0.09 0.92
Seeking social support < - 0.01 0.18 0.99
State-Trait Anxiety Inventory
State-anxiety 0.01 0.07 0.84
Multidimensional Health Locus of
Control Scale
Internal 0.03 0.07 0.67
External 0.06 0.08 0.49
Chance 0.11 0.08 0.15
Respiratory Illness Opinion Survey
Optimism - 0.08 0.10 0.44
Stigma - 0.01 0.05 0.82
Dutch Personality Inventory
Inadequacy 0.05 0.04 0.24
Table 5: Association between psychological factors and medical consultation
due to shortness of breath: Results of logistic regression analysis
Did consult GP Did not consult GP
Did not perceive 5 (22%) 18 (78%) 23 (100%)
Did perceive 46 (41%) 65 (59%) 111 (100%)
51 (38%) 83 (62%) 134 (100%)
Table 4: Perception of shortness of breath as determined by GP consultation
c
2
= 3137; p = 0.08; odds ratio = 2.55
Variable Shortness of breath No shortness of breath p value
FEV1 (ml) 2997 3320 < 0.01
FEV1 % pred 91.9 (90.1–93.7) 98.5 (97.6–99.4) < 0.01
VC (ml) 3827 4149 < 0.01
Reversibility (%) 4.1 (3.5–4.7) 3.0 (2.8–3.2) < 0.01
Pack-years 9.6 7.6 0.01
Current smokers (%) 47.0 33.9 < 0.01
Ex-smokers (%) 31.6 35.5 0.23
Gender (% female) 59.7 53.9 0.09
Age 44.5 43.4 0.14
Table 1: Clinical characteristics of patients who experienced shortness of
breath in the year preceding the screening (n = 285) compared with the rest of
the screened sample (n = 870)
FEV1, forced expiratory volume in 1 s;  FEV1 % pred, FEV1 as percentage of the predicted
value; VC, vital capacity
NB: Reversibility defined as % change in FEV1, 15 min after inhalation of 800 µg salbutamol;
(95% CI)
Variable Did consult GP Did not consult GP p value
FEV1 (ml) 3056 2972 0.41
FEV1 % pred 89.8 (86.6–93.0) 93.0 (90.8–95.2) 0.11
VC (ml) 3954 3759 0.13
Reversibility (%) 5.5 (3.9–7.1) 3.5 (2.9–4.1) 0.01
Pack-years 9.6 9.7 0.93
Current smokers (%) 45.2 47.9 0.66
Ex-smokers (%) 36.6 29.2 0.21
Gender (% female) 59.1 59.8 0.92
Age 41.9 45.8 0.01
Table 2: Clinical characteristics of patients who experienced shortness of
breath in the year preceding the screening and who consulted their GP
(n = 93) compared with those who did not (n = 189) a
aThree subjects answered do not know / do not want to tell
FEV1, forced expiratory volume in 1 s;  FEV1 % pred, FEV1 as percentage of the predicted
value; VC, vital capacity
NB: Reversibility defined as % change in FEV1, 15 min after inhalation of 800 µg salbutamol;
(), 95% CI
ABSTRACT
Objective: To compare the effectiveness of four
classes of anti-asthma medication as initial treatment in
a randomised open study in an asthma clinic setting.
Design and subjects: Eighty-six patients aged 16–70
years were recruited into an open trial following
informed consent.  The diagnosis of asthma was
established by either a 15% diurnal variability in
peak expiratory flow (PEF) or a > 15%
bronchodilation to inhaled salbutamol.  Patients were
randomised to one of the following drug classes: a
short-acting ß2-agonist (n = 21); an inhaled steroid
(n = 25); nedocromil sodium 4 mg qds (n = 22); and
oral theophylline (n = 18).  Symptoms and daily PEF
measurements were recorded on a diary record card.
Results: Baseline characteristics of the four groups
were similar.  Mean FEV1 (predicted) and FVC were
2.61 (82%) and 3.61 (91%), respectively.  Wheeze,
cough and expectoration were present on 4.2, 3.8 and
2.8 days per week.  At one month, the greatest
improvement in number of symptom-free days was
seen in the group taking the inhaled steroids.  Mean
days per week with wheeze fell by 1.3 (p < 0.05),
cough by 0.5 (NS) and expectoration by 1.5
(p < 0.05).  Nedocromil sodium produced a mean
decrease in symptom days of 0.8, 0.3 and 0.8,
respectively (NS).  Other modalities of treatment
produced no significant change in symptoms.  Mean
improvement in FEV1 was greatest in the steroid
group (11%; p < 0.02) followed by nedocromil
sodium (9%; p < 0.02).  There was no change with
short-acting ß2-agonists or theophylline.
Conclusions: Initiation of treatment with anti-
inflammatory therapy produces the greatest
symptomatic and physiological improvement 
in mild asthma.
INTRODUCTION
Therapy for asthma shows wide variation between
countries. 1 In part, this is due to health economics
with cheaper medications, such as theophyllines,
being widely prescribed in developing countries.
Even in countries with sophisticated healthcare, there
are considerable differences in prescribing practices
for the newly diagnosed person with asthma. 2
Our increased understanding of the chronic
inflammatory nature of asthma has led some
authorities to advocate the use of anti-inflammatory
drugs in first-line management. 3 In the UK, despite
widespread knowledge and acceptance of guidelines
recommending the early use of steroids in adults, 
ß2-agonist bronchodilator therapy alone is still the
most widely used first-line treatment. 2
The objective of asthma management is to improve
the quality of life for patients by abolition of
symptoms, improvement of lung function, and
reduction of severity and frequency of exacer-
bations. 4 As the majority of asthmatics are in the
mild-to-moderate category, the first choice of anti-
asthma medication is important both in terms of
achieving these objectives and providing cost-
effective care.  In this study we have examined the
short-term response of the commonly prescribed
asthma medications in a 'real-life' study conducted in
a nurse-run asthma clinic designed to be as similar as
possible to that seen in primary healthcare.
METHOD
The trial was approved by the Local Ethics
Committee.  Patients with mild-to-moderate asthma
were recruited by direct referral from interested
general practitioners or from hospital departments.
Some patients were seen as self-referrals and were
randomised after contact with their GP.  Only
patients not currently taking anti-asthma therapy
were recruited.  Previous occasional use of ß2-
agonist bronchodilators did not preclude entry into
the study.
The diagnosis of asthma was established by the
demonstration of one of the following:
• A 15% diurnal variability in PEF over one week;
• A >15% increase in FEV1 with salbutamol 200 µg
from a metered dose inhaler;
• A reproducible fall of 15% in PEF caused by
exposure to a precipitating factor.
Informed consent was obtained on the initial visit.
Patients were assessed by computerised questionnaire
17. Scheurs PJG, van de Willege G, Tellegen B, et al. Utrechtse
Coping Lijst. Lisse: Swets & Zeitlinger, 1988.
18. van der Ploeg HM, Defares PB, Spielberger CD. The Dutch
version of the Spielberger State-Trait Anxiety Inventory, STAI-
DY. Lisse: Swets & Zeitlinger, 1980.
19. Wallston KA, Wallston BS, DeVellis RF. Development of
the Multidimensional Health Locus of Control Scales. Health
Education Monographs 1978; 6: 160–70.
20. Kaptein AA. Psychological correlates of length of
hospitalization and rehospitalization in acute severe asthma.
Soc Science Med 1982; 16: 725–9.
21. Luteijn F, Starren J, Van Dijk H. Nederlandse Persoon-
lijkheids Vragenlijst. Lisse: Swets & Zeitlinger, 1985.
22. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a ß2-
agonist, terbutaline, with an inhaled corticosteroid, budesonide,
in newly detected asthma. N Engl J Med 1994; 331: 700–5.
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respect.  This is particularly important as there is
evidence that the irreversible loss of lung function
can be minimised by initiating proper treatment at an
early stage. 22 However, when there are patients who
are currently undiagnosed, screening may be the only
option to significantly reduce underdiagnosis.  Our
study revealed that a substantial proportion of the
adult general population had shortness of breath and
only a few of these consulted a GP for this; raising
the question of whether patients were able to
perceive dyspnoea.  Most patients did perceive the
increase in airway obstruction induced by histamine,
but this varied among patients and was related to the
level of induced obstruction.  There was no
difference, however, in the level of perceived
shortness of breath, corrected for covariates, between
those who did and those who did not consult their
GP.  Analysis of the Borg and the VAS ratings of
perceived shortness of breath produced non-
significant results.  From this, it can be concluded
that the level of perception of dyspnoea is unlikely to
be a significant cause for underpresentation and
hence underdiagnosis.  In a dichotomised analysis,
non-perceivers had consulted their GP less
frequently, but this difference was not statistically
significant.
If underpresentation cannot be explained by
differences in perception, personal psychological
characteristics, such as the extent of coping or the
anxiety aroused by a symptom, might offer an
explanation.  However, a number of psychological
tests all failed to reveal differences between the two
groups and the effect sizes were very small,
indicating that the psychological profiles of the
subjects who did and did not consult the GP were
similar.  The analysis had limited statistical power
because of the uneven distribution of medical
consultation (21% vs 79% of the sample), but it is
unlikely that a more even distribution would have
led to significant results.
Age and reversibility were the only two
characteristics that were significantly different
between those who did and those who did not
consult a GP.  The average age of those who
consulted their GP for shortness of breath was
lower, whereas in general, consultation frequency
rose with age.  An explanation for this paradoxical
result might be that the interpretation of the
seriousness of the symptom is different among
different age groups.  Elderly people may interpret
shortness of breath as a natural consequence of
ageing and underestimate its seriousness.  It is not
surprising that reversibility was a significant factor
as an earlier study demonstrated that medical
consultation was significantly associated with
airway variability and a diminished quality of life. 7
The positive predictive value of shortness of breath
for respiratory disease is crucial to the interpretation
of these results.  The DIMCA data confirmed that
shortness of breath may indeed be considered a core
alarm symptom: 83% of all monitored patients with
shortness of breath complied with criteria for early
treatment at some stage during the monitoring.
Thirty-four patients (22%) with shortness of breath
fulfilled criteria for mild-to-moderate asthma or
COPD.  Another 28 patients (18%) with shortness of
breath showed a rapid decline in FEV1 during the
monitoring (> 80 ml/year.), with increased levels of
reversibility and / or bronchial hyperresponsiveness.
Furthermore, 62 patients (41%) with shortness of
breath showed an accelerated decline in FEV1
(> 80 ml/2 years) with mild objective signs of
reversibility or bronchial hyperresponsiveness.  Only
17% of patients who reported shortness of breath
during the year preceding the screening did not meet
the above criteria.
In order to reduce underdiagnosis, GPs should be
aware that a substantial proportion of subjects have
unreported asthma symptoms.  Medical consultation
is not associated with either perception of these
symptoms or with individual psychological factors.
Patients are more likely to consult their GP when the
condition affects their normal daily activities or the
variability of the airways exceeds a certain level,
often in an advanced stage of disease.  Consequently,
early diagnosis may be possible only by means of
active case-finding or screening strategies. n
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ABSTRACT
Objective:  To answer the following question: Are
children with asthma known to their GP?
Methods:  Parents of all 464 children, 1–3 years of
age and registered with five general practices,
received a postal questionnaire asking about asthma
symptoms of the child, and past and present asthma
medication.  Thus, children were classified as having
no, mild, moderate or severe asthma.  The GPs’
records were checked for recorded asthma
symptoms, medication and asthma-related diagnoses.
The presence of these items was compared with
asthma severity.
Results:  Eighty-seven percent of parents responded
to the questionnaire (mean age of children 30.1
months).  For all classes of severity, 75% of children
with asthma were known to their GP.  Although all
children with severe asthma were known to their GP,
the proportion of asthmatic children known to their
GP fell with decreasing severity.  Symptoms and
medication were recorded more often than asthma-
related diagnoses.
Conclusions:  Most preschool children with 
asthma are known to their GP.  The diagnosis is
recorded less often than asthma symptoms and
medication.
with bronchodilators is soundly based.  Our findings
probably reflect the efficacy of inhaled steroids on
airway inflammation.  Bronchial hyper-
responsiveness, a surrogate for airway inflammation,
is improved in these patients. 5,6 In Haahtela’s study of
the long-term treatment of mild-to-moderate asthma
with inhaled steroids or ß2-agonists, 5 there was almost
complete clinical recovery and normalisation of lung
function with confirmed use of inhaled steroids.
In the subgroup of treated patients, bronchial biopsy
specimens showed significant reductions in the
number of inflammatory cells after budesonide
treatment. 7 Those patients who have a poor response
to inhaled steroids are usually those with a more
prolonged history before commencement of anti-
inflammatory treatment. 8 Our study may therefore
provide further evidence for the benefit of early
intervention with inhaled steroids in asthma.
We found that the cromone nedocromil sodium had a
similar spectrum of activity on symptoms and lung
function, but was less potent.  This is consistent with
the known activity of nedocromil sodium being anti-
inflammatory, but to a lesser degree than that of
inhaled steroids.  Within the group of patients
responding to nedocromil sodium, as might be
anticipated, some patients reported considerable
benefit.  Whether such patients respond as well as
they would to inhaled steroids, thereby establishing
nedocromil sodium as a true alternative to inhaled
steroids in a subset of patients, is unknown.
Unfortunately, there appears to be little likelihood of
long-term efficacy studies for this group of
compounds.
What is the best first-choice treatment for patients
with mild-to-moderate asthma?  National guidelines
suggest the use of ß2-agonists as the first choice, with
early intervention with a low-dose inhaled steroid.
The results of our study suggest that those 
patients taking short-acting ß2-agonists are 
following a treatment which does not improve 
lung function and provides poor symptomatic 
relief.  This indicates a need for large-scale studies 
of first-use inhaled steroids in mild-to-moderate
asthma in primary care. n
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for family history, smoking habits, previous episodes of
wheeze and shortness of breath, known allergies
including hayfever and eczema, current medication and
occupation.  Lung function was measured in triplicate
(Vitalograph Compact).  If, at visit one the FEV1 was
<70% predicted, the patient was randomised at this time
otherwise, randomisation took place at visit two after at
least one week of observation.  Serial PEF readings and
symptoms were recorded at home on a diary record
card (DRC).  A salbutamol inhaler could be used as
required throughout the study and, therefore, all patients
were instructed on inhaler technique, which was
assessed at each visit.
Patients were randomised following baseline
assessment from a computer-generated list designed
to provide balanced recruitment to one of four
classes of asthma medication.  The medication was
administered in an open fashion and efficacy was
assessed over a one-month period.  Where possible,
patients were randomised to one of two formulations
within each class to ensure applicability of the results
as a class effect.  The four drug classes were:
• A short-acting ß2-agonist (Aerolin Autohaler 200 µg
prn or Bricanyl Turbohaler 0.5 mg prn; n = 21);
• An inhaled steroid (Becotide 200 µg bd or
Pulmicort Turbohaler 100 µg bd; n = 25);
• A cromone (nedocromil sodium 4 mg qds; n = 22);
• Oral theophylline (Nuelin 250 mg bd or Theodur
300 mg bd; n = 18).
Once randomised, the patient was required to
complete a DRC for one month, recording serial PEF
readings, daily symptom scores on a scale of nought
to nine, night-time disturbance and daily use of relief
medication.  If the patient was randomised to
theophylline subsequent visits were arranged to
assess theophylline blood levels until therapeutic
levels of 10–20 mg/l were achieved.
In the event of an adverse reaction or worsening of
DRC symptoms, patients were instructed to contact
the clinic as soon as possible to discontinue the
medication and introduce second-line medication.
ANOVA was used to determine the degree of
statistical significance of any differences between
treatment arms in changes from baseline values
following one month’s treatment.
RESULTS
Baseline characteristics of the four groups were
similar; mean FEV1 (predicted) was 2.61 (82%);
FVC was 3.61 (91%).  Wheeze, cough and
expectoration were present on 4.2, 3.8 and 2.8 days
per week (Table 1).
At one month, the greatest improvement in the
number of symptom-free days was seen in the group
taking inhaled steroids.  Mean days per week with
wheeze fell by 1.3 (p < 0.05) cough by 0.5 and
expectoration by 1.5 (p < 0.05).  Nedocromil sodium
produced similar but less striking results (0.8, 0.3
and 0.8, respectively; NS).  Other modalities of
treatment produced no significant change in
symptoms (Table 2).  In this group of people with
mild asthma mean improvement in FEV1 was
greatest in the steroid group (11%; p < 0.02) followed
by the nedocromil sodium (9%; p < 0.02).  There was
no change with short-acting ß2 agonists or
theophylline (Table 2).
DISCUSSION
In this comparison of four commonly prescribed
therapies for mild asthmatics, we have confirmed the
efficacy of inhaled steroids both in reducing
symptoms and improving lung function.  A similar,
but less marked, improvement was seen with
nedocromil sodium.  There was no overall
improvement with bronchodilator therapy alone.
Our patients were relatively naïve to asthma
treatment, having previously only received inhaled
bronchodilator medication or no therapy at all.  They
were thus very similar to many asthmatics seen in
the early stages of the disease in primary care.  In an
attempt to mimic the clinical setting, it was decided
to administer the medication in an open-label
fashion.  Although this prohibits any definite
conclusions being drawn as to the absolute efficacy
of the medications studied, it does allow for
comparisons to be made between treatment groups.
Previous studies have demonstrated the
bronchodilating effect of inhaled steroids in mild-to-
moderate asthma even in subjects whose symptoms
are not troublesome. 5 The striking finding of our
study is that inhaled steroids were effective not only
in terms of lung function, but also in reducing the
number of symptomatic days even after only one
month of treatment whereas inhaled bronchodilators
had no clinically important effect on symptom
frequency.  It is questionable as to whether the
current recommendation that treatment be initiated
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Preschool children with asthma: Do their GPs know?
M.J.A. Tasche, J.H.J.M. Uijen, B.P. Ponsioen, L.W.A. van Suijlekom-Smit, J.C. de Jongste and J.C. van der Wouden
Baseline Steroid Cromone Theophyline ß2-agonist
FEV1 (SD) %predicted 2.8 (1.3) 84.7 2.3 (1.1) 71.2 2.6 (1.2) 73.7 2.5 (0.8) 81.9
FVC (SD) %predicted 4.0 (1.4) 98.7 3.4 (1.2) 90.4 3.7 (1.3) 87.9 3.4 (1.1) 93.9
Days per week with 
wheeze (SD) 4.3 (3.1) 5.0 (2.7) 5.4 (2.2) 3.3 (3.2)
Days per week with
cough (SD) 3.7 (3.3) 4.6 (3.1) 2.8 (3.0) 4.3 (3.2)
Days per week with
sputum (SD) 3.0 (3.2) 4.1 (3.3) 1.8 (2.3) 2.6 (3.2)
Table 1: Baseline characteristics of patients enrolled into the study
After one month Steroid Cromone Theophyline ß2-agonist
FEV1 (SD) 3.1 (1.5)** 2.5 (1.2)* 2.6 (1.5) 2.5 (1.0)
FVC (SD) 4.1 (1.7) 3.4 (1.3) 3.7 (1.5) 3.3 (1.3)
Days per week with 
wheeze (SD) 3.0 (2.6)* 4.2 (3.0) 3.8 (2.9) 3.5 (3.2)
Days per week with
cough (SD) 3.2 (3.2) 4.3 (3.2) 3.5 (3.2) 4.1 (3.5)
Days per week with
sputum (SD) 1.5 (2.0)* 3.3 (3.3) 1.9 (2.7) 2.4 (3.3)
Table 2: Lung function and symptom scores following one month of treatment
*p < 0.05, **p < 0.02
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showed no differences between responders and non-
responders with respect to the GPs’ recorded
information on contact frequency and the presence of
asthma-like symptoms, diagnoses and medication.
Forty percent of the non-responders were from ethnic
minorities (Morocco and Turkey) compared with
14% in the total population (p < 0.01).
Of the 404 children for whom questionnaires were
completed, 281 (70%) did not suffer from asthma.
According to our criteria, 98 (24%) were classified as
having mild asthma, 17 (4%) as having moderate
asthma and 8 (2%) as having severe asthma.
Asthma symptoms were recorded in 35% of the 464 files
of children 1–3 years of age (Table 2).  The distribution
of these asthma symptoms in the GPs’ files showed some
overlap between different items.  Chest congestion with
or without sputum production was recorded most
frequently, followed by wheezing and rhonchi.
In nearly 32% of all records, the general practitioners
prescribed specific asthma medication, including
deptropine, an anticholinergic drug which is
frequently prescribed in the Netherlands, but is
uncommon elsewhere. 7 The prescription frequencies
of specific asthma drugs are shown in Table 3.  For
reasons of comparison with other countries, we
present figures with and without deptropine.  When
deptropine prescriptions were excluded, the
prescription of specific asthma medication
consequently dropped from 32% to 11%.
Asthma-related diagnoses were registered by GPs in
20% of the files (Table 2).  Acute bronchitis was
recorded most frequently.  To answer the main
question, we compared questionnaire data with the
GPs’ records.  The data from the records for each
degree of asthma severity, found in the parental
questionnaire, is shown in Figure 1.
All children with severe asthma were known to their
GP (either by diagnosis or asthma medication).  The
proportion drops with falling levels of severity.
Asthma-like diagnoses were recorded in fewer
children than both asthma symptoms and medication.
For all classes of severity combined, 75% of children
with asthma are known to their GPs.
DISCUSSION
The return of 87% completed questionnaires was
similar to that of other studies on this subject. 10,11 A
substantial percentage (40%) of the non-responders
were from ethnic minorities, who may have had
difficulties understanding the questionnaire.
By focusing on information recorded by GPs, we
may have underestimated the number of known
asthmatics.  If we had asked the GP directly: ‘Does
this child have asthma?’, more cases would probably
have been classified as ‘known’.  We suspect this
latter method of data collection would be more liable
to bias than checking for information that was
actually written down during patient care. 15
In this study, discrepancies between the two sources
of information may partly be explained by the effect
of time.  As the diagnosis of asthma is seldom made
in a single consultation, there may be patients who
are still on their way to being diagnosed by their GP
among the children we have labelled as ‘asthmatic’.
Furthermore, questions regarding the diagnosis of
mild asthma in this age group and the consequences
of this diagnosis for future respiratory disease are
still unsolved. 16,17 Another aspect of time worth
mentioning is reflected in the expectation that many
children with airway symptoms will grow out of
them, especially in this age group where viral
infections may cause asthma-like symptoms. 18
Of all items recorded by GPs, medication was the
best recorded.  Recorded asthma medication was
mostly deptropine, an oral drug with anticholinergic
properties.  Use of this drug is in accordance with
the previous version of the guidelines for asthma in
childhood issued by the Dutch College of General
Practitioners. 19 If deptropine had been unavailable
(as in other countries), we assume that other drugs
would have been prescribed.  Antibiotics were
excluded from our search as their prescription for
asthma is not advised.
The limited number of practices included in our
study means that the conclusions should be
generalized with caution.  Regarding the affiliation
with the Department of General Practice, the chance
of selection bias will be small as several hundred
practices have contact with the Department for
teaching, vocational training and research activities.
None of the practices that participated in this study
had been involved in any previous study in the field
of childhood asthma.
For the practices studied, our results indicate that
most children with probable asthma are known to
their general practitioners.  Our results also indicate
that both recorded asthma symptoms and specific
asthma medication are more sensitive pointers for
detecting children with asthma from GPs’ files than
specific diagnoses of asthma or asthma-like
disorders. n
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INTRODUCTION
Speight highlighted the underdiagnosis and undertreatment
of childhood asthma more than 15 years ago. 1 In a
general practice audit by Levy and Bell, only one-third of
asthmatic children had their illness diagnosed before the
age of four years, despite most having presented with
respiratory symptoms by this age. 2 Since then, this
subject has been of increasing interest to researchers,
clinicians and general practitioners.  This is reflected in the
publication of various consensus reports during the last
few years. 3–6 We would expect more children with
asthma-like symptoms to be known to their GPs.
The prevalence of asthma in 0–3-year-olds is high;
rates vary from 5% to 31% according to the definition
of asthma and methods used for identifying cases.
Guidelines for appropriate therapy have been widely
disseminated and publicised 3-6 and some authors have
argued that this process may improve long-term
prognosis. 7,8
By studying GPs’ medical records of children, Neville
found that 32% were potentially asthmatic. 9 No
attempt was made, however, to validate these findings
by interviewing parents. Strachan 10 reviewed general
practice records of 369 children at seven years of age:
31% had some record of wheeze.  He compared the
records with data from parental questionnaires of 174
of these children, and concluded that parental recall of
early episodes is incomplete and biased by the severity
and persistence of the symptoms of the child.
In the Netherlands, every patient is registered with a
general practitioner who acts as ‘gatekeeper’ to
secondary care.  This offers a comprehensive
sampling base for asthma research.  We compared
GPs’ medical records of children with parental
questionnaires to answer the following question: Are
preschool children with asthma known to their GP?
METHODS
Parents of all 464 preschool children (1–3 years old) in
five general practices received a postal questionnaire
through their GP.  Two weeks later, a reminder was sent
to non-responders.  The practices (both rural and urban
areas; nine general practitioners), which were affiliated
with the Department of General Practice of Erasmus
University, had no special interest in asthma (no clinics
or asthma nurses).
As there is no suitable and well-validated questionnaire
for assessing asthma in this age group, 11 we devised
one of our own by adopting validated questions from
previously developed questionnaires. 12–14 Our
questionnaire contained items about asthma symptoms
(such as wheezing, dyspnoea), past and present asthma
medication, and morbidity experienced by the child.
Based on the answers received, the children were
classified as having no, mild, moderate or severe
asthma (Table 1), according to recurrent airway
symptoms and use of specific asthma medication. 2–5
Peak expiratory flow measurements are not possible
in most preschool children.  Jones et al. showed that
asthma symptoms are closely related to results of
lung function tests in children over five years. 12
We examined general practitioners’ records (some
handwritten, some computerised, some both) of these
children, checking them for asthma symptoms,
specific asthma medication and asthma-related
diagnoses (asthma, acute bronchitis, chronic non-
specific respiratory disease) since birth.  The two
people who studied the files were unaware of the
answers in the parental questionnaire.
Asthma severity, based on questionnaire answers, was
compared to asthma symptoms, specific asthma
medication and asthma-like diagnoses found in the
general practitioners’ records.  Data were analysed with
SPSS-PC.  Differences between responders and non-
responders were tested by means of a c 2 test (p < 0.05).
RESULTS
A total of 404/464 (87%) parents responded to the
questionnaire.  Analysis of the non-responders
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No asthma
no respiratory symptoms and no medication
Mild asthma
dyspnoea at least twice in past 12 months
wheezing 4 to 12 times in past 12 months
present weekly use of bronchodilators for less than6 weeks
present daily use of deptropine for less than 6 weeks or deptropine use in past 12
months
if doctor ever said to parents their child has asthma
if parents think their child has asthma now
Moderate asthma
wheezing less than12 times in the past 12 months
‘yes’ to at least two out of the three following questions: 8
Wheezy or asthmatic condition once or more per week?
Hampered in daily activities (feeding, play, going to school or creche)?
Awakened by coughing or wheezing during night-time?
present use of sodium cromoglycate or ketotifen
present use of deptropine for 6 or more weeks
present daily use of bronchodilators
present weekly or monthly use of bronchodilators for 6 weeks
use of corticosteroids for less than 3 weeks in past 12 months
Severe asthma
all three following questions answered ‘yes’.8
Wheezy or asthmatic condition once or more per week?
Hampered in daily activities (feeding, play, going to school or creche)?
Awakened by coughing or wheezing during night-time?
use of corticosteroids during 3 or more weeks in past 12 months
present use of corticosteroids
Table 1: Classification of asthma severity according to questionnaire answers
Asthma symptoms
All asthma symptoms 163 (35.1)
chest congestion or phlegm 74 (15.9)
wheeze 63 (13.9)
rhonchi 63 (13.6)
nocturnal cough 37 (8.0)
dyspnoea 35 (7.5)
Asthma-related diagnoses
All asthma-related diagnoses 93 (20.0)
acute bronchitis 71 (15.3)
chronic non-specific respiratory disease 43 (9.3)
asthma 2 (0.4)
Table 2: Number (%) of GPs’ files (n = 464) containing asthma symptoms 
or diagnoses
Specific asthma medication
All asthma medication 148 (31.9)
deptropine 137 (29.5)
All asthma medication (deptropine excluded) 51 (11.0)
ß2-sympaticomimetics 34 (7.3)
ketotifen 30 (6.5)
ipratropium bromide 7 (1.5)
corticosteroids 7 (1.5)
sodium cromoglycate 5 (1.1)
xanthines 3 (0.6)
Table 3: Number (%) of GPs’ files (n = 464) with specific asthma medication
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patients attending the ‘asthma’ clinic had COPD, and
to assess the use and impact of the management
guidelines within our practice.  The secondary aim
was to assess the effect on prescribing costs of
implementing a policy of stopping inhaled steroids in
patients with irreversible airway obstruction.
METHODS
The study group consisted of all patients aged over
39 years who were attending the nurse-led clinic,
which is supported by two general practitioners with
an interest in respiratory disorders.   The practice
used two spirometers: the first, a small vane type
(Medical Micro Ltd), was used for screening and in
GP consultations.  The second was a fully
computerised type (Vitalograph 2120), which needed
calibration whenever it was set up and was used by
the nurse during asthma clinics.  Being more
accurate, it also was used to check the findings of the
microspirometer.
The practice has one half-time and five full-time
doctors caring for 10,700 patients [47% (5030) aged
over 39 years].  It is located in the northern suburbs
of Plymouth and extends to the southern fringes of
Dartmoor in southwest Britain.  There is a wide
range of social class with a deprivation index close
to the national average.
Protocols
The protocols were designed in conjunction with
Professor D. Shale of the Department of Respiratory
Medicine at the University of Wales School of
Medicine.  The following were agreed by the
primary care team.
All patients over 39 years of age attending the
asthma clinic should have diagnosis by spirometry.
If the FEV1 was more than 80% of expected or the
FEV1: FVC ratio was more than 75%, COPD was
excluded.  Others had spirometry repeated and, if
still low, underwent reversibility assessment.  Those
who could be reversed, by the methods listed below,
to normal FEV1 or FEV1: FVC ratio were diagnosed
as asthma, the remainder with persistent airflow
obstruction were deemed to have COPD.
Reversibility assessment
Reversibility was defined as a variation in FEV1 or
peak expiratory flow (PEF) of more than 20%.  This
was checked by the following methods:
1. Informal: Recent recordings of lung function in
the patient’s notes at times showed sufficient
variability to confirm reversibility, for instance,
before and after a course of prednisolone.
2. ß2-agonists: By using 5 mg of salbutamol by
nebuliser, acceptable alternatives include
salbutamol, terbutaline or ipratropium bromide
metered-dose inhaler via large volume spacer.
Dramatic changes in FEV1 or PEF are suggestive
of asthma rather than COPD and merits
reconsideration of the diagnosis.  The two
conditions can coexist.
3. Inhaled corticosteroids: By using two to three
months of high-dose inhaled corticosteroids
(beclomethasone dipropionate or budesonide
800–1000 µg or fluticasone propionate 
500 µg daily).
4. Oral steroids: Two weeks of prednisolone at a
dose of 30 mg daily.
Chest X-ray
A chest X-ray was recommended within two years of
diagnosis and at least once every five years thereafter.
Minimum data recording
We agreed that the minimum data set would be
recorded in all patients notes.  Smoking habits were
recorded as past exposure (best expressed as pack-
years)1 and current status.  Smoking advice was
recorded and leaflets were made available for patients
to take home.
The presence of other pulmonary conditions was
recorded, for example, tuberculosis and bronchiectasis
as well as other significant medical conditions such as
ischaemic heart disease, osteoporosis and diabetes.
Vaccination status
In our practice, we recommend influenza
immunisation annually.  We agreed that we would
record whether patients were advised to have the
vaccine, and if and when it was administered.
Pneumococcus immunisation was recommended to be
administered on one occasion for all patients,
according to current Department of Health advice.5
RESULTS
Fifty-eight adults over 39 years of age attended the
asthma clinic in the preceding 12 months.  After
spirometry according to the protocols, 35 / 58 (60%)
patients were diagnosed as having COPD.  The mean
FEV1 was 1.3 l, range 0.34–2.40.  Table 1 shows the
grade of severity and results of reversibility testing in
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ABSTRACT
Objectives: To identify and assess the management
of patients with COPD attending our practice asthma
clinic by implementing protocols for the diagnosis
and management of COPD, including reversibility
testing.
Design and subjects: All patients aged over 39
years attending the asthma clinic at The Roborough
Surgery were included.  We assessed the
implementation of the protocols and analysed
prescribing data in those found to have irreversible
airflow obstruction.
Results: COPD was found in 35/58 adults (60%)
over 40 years, of these, 6 (17%) were irreversible.  In
irreversible patients, less inhaled steroids were
prescribed, but this was offset by more
anticholinergic prescriptions.  The majority had had
appropriate diagnostic tests, but the uptake of
immunisation was 51% for influenza and 43% for
pneumococcal infection.
Conclusion:  Applying COPD protocols did not
reduce prescribing costs, but encouraged optimum
patient care in terms of investigations, diagnosis,
appropriate treatment and immunisation.
INTRODUCTION
It has been stated that most patients with COPD have
irreversible airway obstruction. 1,2 These patients
often receive expensive, but ineffective, drug
treatment. 3 As the disease progresses and they
become more breathless, more treatment is added,
with increased prescribing costs.  Reversibility
testing is useful in excluding chronic asthma from
COPD and establishing whether drug therapy is
likely to be beneficial.  It has been predicted that
large savings could be made if reversibility testing is
systematically applied to patients with COPD in
primary care. 3
In June 1996, the surgery introduced protocols for the
diagnosis and management of COPD agreed by
partners and nurses.  These include reversibility
testing, appropriate investigations, smoking advice,
vaccination and treatment review.  The protocols were
produced in conjunction with British Thoracic Society
(BTS) members, but preceded the publication of the
BTS guidelines. 1 They are compatible with the
European Respiratory Society (ERS) guidelines. 4 The
primary aim of this audit was to establish how many
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Figure 1: Methods by which reversibility was confirmed in 20 patients, aged
over 39 years, with COPD who were attending an asthma clinic in a general
practice
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Figure 1: Proportion of asthmatic children known to their GP as indicated by
registered symptoms, diagnoses and medication, shown according to degree
of asthma severity
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those identified as having COPD.  Reversibility was
demonstrated in 29/35 (83%) patients; the diagnosis
was made most frequently by informal assessment
from the records (Figure 1).
Prescribing data were analysed for six months before
and after reversibility testing for those deemed to
have irreversible obstruction (six patients; Table 2).
Three patients with irreversible disease were on
inhaled steroids – two stopped and one continued as
his cough became worse after stopping.  The
reduction in the cost of inhaled steroids, however,
was offset by the increase in anticholinergic
prescriptions which were more likely to be supplied
after attending the asthma clinic.  Of 17 patients
started on inhaled anticholinergic therapy, 70% are
continuing long-term.
In the patients diagnosed as having COPD, a chest X-
ray was performed within two years of diagnosis in
57%, within the last five years in 71%, but five patients
(14%) had no chest X-ray at diagnosis or in the last five
years.  Immunisation for influenza within the last 12
months occurred in 51%, and for pneumococcal
infection within the last five years in 43%.
Three of the 35 patients were taking ß-blockers at the
time of assessment; one was on aspirin and another
on an oral non-steroidal anti-inflammatory agent.
DISCUSSION
This audit was limited to patients attending the
asthma clinic and is not necessarily representative of
all patients with COPD attending the surgery.
It is believed that airflow reduction in COPD is
usually irreversible. 1,2,4 However, data from the USA
demonstrated that up to two-thirds of patients with
COPD have a significant response to inhaled
bronchodilators. 6,7 Of our patients with COPD, 29
out of 35 (83%) demonstrated evidence of
reversibility.  In practical terms, reversibility testing
was easy: two-thirds could be assessed in minutes
either via review of records or by response to
nebulised bronchodilator.  As in the case of the ERS
statement, 4 our guidelines originally did not include
a minimum 200 ml increase in FEV1, as
recommended by the BTS guidelines, but were
supported by (PEF) monitoring.  We now suggest
adherence to the BTS recommendation.  As the PEF
is less reliable, it may be misleading in COPD
reversibility assessment especially in more severe
cases, so there is an argument for the use of
spirometry.
There are practical difficulties in stopping inhaled
steroids in patients with irreversible COPD: They
tend to have more severe disease and do not always
take kindly to having their treatment reduced when
they are getting worse.  Even if there are no
objective changes in spirometry, this does not
necessarily mean that they are not benefiting from
anti-inflammatory treatment.  In such situations, it is
difficult to blindly follow guidelines and stop inhaled
steroids rather than listen to the patient.  After all the
guidelines still suggest using bronchodilators which
may be equally ineffective.
As only a small minority of our patients with COPD
was irreversible and had their prescriptions reduced,
reversibility testing may not lead to marked
reductions in prescribing costs in COPD.  However,
these results need to be considered cautiously as our
numbers were small and may not be representative of
other populations of COPD patients in primary care.
The findings do justify a larger multicentre study;
such a study is due to start shortly.
The process of systematic review of patients with
COPD may, in fact, increase costs as other drugs
may need to be added.  Anticholinergic drugs have a
particular place in COPD 8,9 and we have advocated a
trial of this therapy; 70% of those patients who
started, continued to use these drugs.  In this sample
of patients, none were receiving regular oral steroids,
theophyllines or long-acting bronchodilators.
Despite active encouragement, our influenza
vaccination rates are unacceptably low,
demonstrating the need for a register of those at risk
to check that they are invited at the right time and
that they attend.  We also had low rates of uptake of
pneumococcal immunisation, but this may be less
important and is not routinely recommended by the
British or European guidelines on COPD. 1,4
The value of performing a chest X-ray in all cases is
debatable.  It is helpful to exclude other pathology, such
as carcinoma of the bronchus.  The X-rays in this group
did not reveal any major pathology which required
subsequent management.  The BTS guidelines
recommend chest X-rays in moderate-to-severe disease
only, unless other symptoms are present.  Previously,
three patients in our practice had presented with cough,
wheeze and a positive response to inhaled steroids, and
subsequently proved to have bronchial carcinoma.
Therefore, our guidelines err on the side of caution.  In
this group, it was encouraging that chest X-rays had
been performed in the majority (86%) albeit that not all
were done at diagnosis or in the last five years.
ß-blockers, aspirin and non-steroidal anti-inflammatory
drugs are known to sometimes cause respiratory
problems.  Three patients attending the asthma clinic
were being prescribed ß-blockers; these were
discontinued immediately with beneficial clinical effect.
Iatrogenic causes of airway obstruction should not be
overlooked; auditing patients helps to avoid such
pitfalls.
CONCLUSION
Our study describes a method for diagnosis and
management of patients with COPD in general practice.
Use of COPD protocols in patients attending the asthma
clinic optimised patient care in terms of investigations,
diagnosis, appropriate treatment and immunisation.  We
were, however, unable to reduce our prescribing costs
through inappropriate use of inhaled steroids in patients
with irreversible airway obstruction.  Further larger
studies in this area are needed.n
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Editor
Dr Sheikh comments on the common association of
rhinitis and asthma in his paper on ‘Asthma and co-
existent disease’ (Asthma in Gen Pract 1998; 6(2):
15–18).
This was a personal problem for me, as I am an
asthmatic.  Effective treatment is to exhale through
the nose after inhaling the preventive steroids
prescribed for asthma.  This is simple but seems to
be little known.
Dr G S Plaut
Halstead, Essex, UK.
Editor,
Dr Plaut suggests that asking patients to exhale (via
the nose) their inhaled asthma steroids is effective
treatment for co-existent rhinitis.  Whilst this sounds
plausible, and may be of benefit to some patients, as
far as I am aware, there is no published evidence
supporting the routine use of such a strategy. 1
Highly effective, proven treatments for rhinitis,
however, do exist and I would suggest that these are
employed as first-line treatment options. 2
Dr A Sheikh
Imperial College School of Medicine, London, UK.
1. Lund VJ, Aaronsen D, Bousquet J, et al. International
consensus report on the diagnosis and management of rhinitis.
Allergy 1994; 49(Suppl 19): 1–34.
2. Sheikh A. Rhinitis: fact sheet. GPIAG (in press).
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Letter to the Editor
Steroid ß2-agonist Anticholinergic Combination antichol/
inhalers inhalers inhalers ß2-agonist
inhalers
Before 11 31 6 10
After 8 31 13 15
Change
in costs - £ 58.50 0 + £ 29.40 + £ 32.50
Table 2: Changes in prescribing for six patients shown to be irreversible on
formal testing.  The figures represent total numbers of inhalers prescribed for
these patients for six months before and six months after reversibility testing
Reversible Irreversible
All 29 6
Mild 10 1
Moderate 11 3
Severe 8 2
Table 1: Grade of severity of air flow obstruction and results of reversibility
testing in 35/58 patients with COPD attending the asthma clinic
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